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Abstract
Chronic toxicities of locoregional and systemic oncological treatments commonly develop in long-term cancer
survivors. Amongst these toxicities, post-radiotherapeutic complications alter patient’s quality of life. Reduction of
exposure of normal tissues can be achieved by optimization of radiotherapy. Furthermore, understanding of the
fibrogenic mechanisms has provided targets to prevent, mitigate, and reverse late radiation-induced damages. This
mini-review shows how (i) global molecular studies using gene profiling can provide tools to develop new
intervention strategies and (ii) how successful clinical trials, conducted in particular with combined pentoxifylline-
vitamin E, can take benefice of biological and molecular evidences to improve our understanding of fibrogenic
mechanisms, enhance the robustness of proposed treatments, and lead ultimately to better treatments for patient’s
benefice.
Introduction
Therapeutic management of cancer improved during the
past decade and is characterized today by a significant
increase in patient’s survival rates. Although effective on
cure rates, both locoregional and systemic oncological
treatments present some concerns related to develop-
ment of chronic toxicities that alter patient’s quality of
life, while results of combined therapies suggest that
normal tissue toxicity will become a major concern
within the next years. Amongst these toxicities, radiation
enteropathy is a significant delayed side effect of lumbar
and pelvic radiotherapy.
The risk, severity and nature of these radiation-induced
toxicities depend on several factors including radiother-
apy-related factors (total dose, dose per fraction and
volume exposure) and patient-related factors (comorbid-
ities) [1]. Accordingly, a real effort has been made to
reduce normal tissue exposure by ballistic and imaging
optimization of radiotherapy. Besides technological tools,
understanding the fibrogenic mechanisms and targeting
profibrotic factors has provided alternate and promising
approaches to prevent, mitigate or even reverse late radia-
tion-induced damages [1,2].
If today’s clinical practice always aims to limit aggra-
vating factors, current management of radiation-induced
damages involves [3]: (i) anti-inflammatory treatments
including corticosteroids; (ii) vascular therapy including
pentoxifylline (PTX) or hyperbaric oxygen; (iii) antioxi-
dant treatment including superoxide dismutase in the
nineties and then combined pentoxifylline-vitamin E
(PTX-VitE) in the last decade.
The first part of this mini-review shows how global
molecular studies using gene profiling can provide tools to
develop new intervention strategies with old molecules or
new compounds. The second part shows how successful
clinical research done with well-known but low potent old
drugs takes benefice of biological and molecular evidences
to improve its robustness for patient’s benefice.
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From molecular profiling to new intervention
strategies
Cellular and molecular mechanisms involved in the
persistence of radiation fibrosis
In all irradiated tissues and especially when vital organs
like the heart, lung or intestine are affected [4], the most
concerning aspect of radiation fibrosis is its progressive
and seemingly irreversible evolution. Thus, the develop-
ment of curative anti-fibrotic strategies is nowadays highly
anticipated by both patients and physicians [5]. Definition
of new biologically-based anti-fibrotic strategies is there-
fore an attractive option to be achieved by characterization
of the cellular and molecular mechanisms involved in the
persistence of radiation fibrosis.
In human radiation enteropathy, fibrosis is the main his-
topathological hallmark [6]. Fibrosis contributes to the
loss of intestinal compliance and impaired intestinal func-
tion and we showed that it was associated with heavy
deposition of Connective Tissue Growth Factor (CTGF/
CCN2) [7]. CTGF gene regulation is known to be under
the control of TGF-b via a Smad consensus sequence and
TGF-b RE/BCE-1 binding sites located in the CTGF pro-
moter region [8,9]. We showed that, surprisingly, TGF-b1
expression in fibrotic area was low during the onset of
radiation enteropathy [7]. The molecular basis of this
paradox was investigated using (i) a high-throughput bio-
logical approach by cDNA array profiling and (ii) a classi-
cal biochemical approach with recombinant TGF-b1 and
CTGF. These studies were performed with unique and
physiologically relevant cell models, employing primary
smooth muscle cells and sub-epithelial myofibroblasts
derived from radiation enteropathy. These cells mimic
fibrosis in vitro, as they maintain their fibrogenic features
in long term culture (6-8 passages) i.e. altered contractile
function, modification of the actin cytoskeleton and
increased secretory activity [10,11].
The comprehensive cDNA approach showed activation
of the Rho/ROCK pathway [12]. Further functional in
vitro experiments showed that this intercellular signaling
pathway controls CTGF expression in intestinal smooth
muscle cells and in subepithelial myofibroblasts derived
from radiation enteropathy [10,13]. In addition, our gene
profiling studies showed that radiation enteropathy was
associated with a global deregulation of the extracellular
matrix remodeling with increased ECM deposition,
MMPs and TIMPs activity [14]. Whether this dynamic
remodeling process was the cause or the consequence of
the phenotypic alteration of the resident mesenchymal
cells is currently under investigation.
Cell response to increasing concentrations of recombi-
nant TGF-b1 was investigated. Activation of cell-specific
signaling pathways by low TGF-b1 concentrations was
demonstrated with a prominent activation of the Rho/
ROCK pathway in fibrosis-derived cells, whereas the Smad
pathway was predominantly activated in normal cells. This
differential fibrogenic response identified in normal versus
fibrosis-derived cells opened new therapeutic opportu-
nities for targeted anti-fibrotic therapy. In addition, we
showed that recombinant CTGF was able to trigger its
auto-induction in fibrosis-derived cells, an effect which
was further enhanced by TGF-b1. These results thus iden-
tify specific and combinatorial roles of low TGF-b1 doses
and CTGF for the maintenance of tissue fibrosis [15].
From physiopathological mechanisms to clinical transfer
Rho GTPases regulate fundamental cellular processes
including cell motility, cell cycle progression, cell survi-
val, transcription, membrane trafficking and cytokinesis
via their downstream effectors the Rho-associated
kinases (ROCKs) [16,17]. Many Rho functions have
been elucidated using pharmacological inhibitors, the
most prominent ones being Statins, molecules which
inhibit isoprenoid intermediates production and Rho
activation. In order to investigate whether the Rho/
ROCK cascade regulates radiation-induced fibrogenic
program in intestinal mesenchymal cells, pharmacologi-
cal inhibition of Rho and ROCK activation was per-
formed in vitro using pravastatin and Y-27632, a
pyrimidine derivative inhibitor of ROCK. We showed
that both agents modulated radiation-induced fibrogenic
differentiation and the expression of CTGF, TGF-b1,
and collagen Ia2 genes (Figure 1), most likely via NF-
B inhibition [10,11,18]. Next, therapeutic experiments
were conducted in pre-clinical models. Pravastatin was
chosen as, in the case of convincing results, it would be
easy to accelerate the transfer of this drug to the clinic,
given the fact that the drug is safe and well tolerated
[19]. Remarkably, we showed that pravastatin administra-
tion with curative intent improves radiation enteropathy
in rats, inhibits Rho and ROCK activity in human sam-
ples, and subsequently inhibits CTGF production in-vivo,
ex-vivo, and in-vitro. In addition, inhibition of type-I-col-
lagen and fibronectin occurred, indicating that pravasta-
tin modulates the secretory phenotype of mesenchymal
cells, probably by inhibition of the Rho/ROCK/CTGF/
ECM cascade [13]. Mitigation experiments with pravasta-
tin, relevant to clinically well-established fibrosis,
improved delayed radiation enteropathy in rats and
decreased both CTGF expression and collagen deposi-
tion. Interestingly, pravastatin’s protective effect was dif-
ferential, as no tumor protection occurred [20]. Similar
results were obtained by others using Simvastatin [21]
and anti-fibrotic efficacy of statins was shown in model
of radiation-induced lung [22,23]. These pre-clinical find-
ings encouraged us to propose a phase II randomized
clinical trial, which received approval from the local
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ethics committee and started at Institut Gustave Roussy
in January 2010 with the support of the French Ministry
of Health (PHRC 2010).
Searching for anti-fibrotic treatment using molecular tar-
gets lead to the development of targeted drugs. Amongst
them anti-CTGF antibody [24], imatinib (anti-PDGF anti-
body) [25-27], statin (Rho/Rock-inhibitors) [20-23,28] have
demonstrated efficacy in pre-clinical studies and need now
to be validated in clinical trials. Two targeted drugs have
recently showed interesting results in recent trials: the
small molecule inhibitor of TGF-b1, pirfenidone, and the
tyrosine kinase inhibitor, BIBF 1120. Both of them halt
progression of idiopathic pulmonary fibrosis [29,30]. Still
others, such as combined pentoxifylline-vitamin E has a
proven clinical efficacy with an unknown mechanism of
action [31-38].
From clinical trials to understanding the
molecular mechanism
In the nineties an antioxidant compound, the liposomal
Cu/Zn superoxide dismutase (SOD), was the first drug to
half reduce established radiation fibrosis in patients and
experimental models (reviewed in [3]). Biological studies
showed that SOD inhibited TGF-b1 and TIMPs and lead
to a subsequent reversion of the myofibroblastic pheno-
type in vitro [39,40]. Later, Delanian et al. showed that
combined PTX-Vit.E administered to patients, half
reduced superficial radiation fibrosis in 6 months [31].
Results were confirmed in a randomized clinical trial [32]
and by long-term clinical results (3 years) [33]. A first
experimental study using skin fibrosis in pig as model
showed that the histopathological recovery after PTX/
VitE treatment was associated with significant reduction
of TGF-b1 deposition [41]. Since then, numerous clinical
trials were successful and showed improvement of
osteoradionecrosis [34], superficial fibrosis [36], proctitis/
enteritis [37], pelvic complications [38], uterine fibro-
atrophy [35,42]. Moreover, combined PTX-Vit.E in rat
experiment had beneficial effects on radiation-induced
myocardial fibrosis and left ventricular function [43].
Recent report using a triple combination PENTOCLO:
PTX-VitE and clodronate; a biphosphonate active against
macrophages also allows successful healing of severe
osteoradionecrosis [44] and reduction of neurological
Figure 1 A. Effect of Pravastatin on mRNA expression of TGFb1, CTGF and Collagen in a kinetic manner: Twenty four hours kinetics of
mRNA expression of TGFb1, CTGF, and Col Ia2 in control and Pravastatin treated cells show that Pravastatin treatment with a dose of 0.1 mM
and up reduces levels of mRNAs of these genes with maximum efficiency at six hours post-treatment; C: control, P: Pravastatin treatment. 0.1,
0.5, and 1 refer to treatment dose in mM. *: p < 0.05, **: p < 0.01, ***: p < 0.005 according to kruskal-Wallis test. B. Protein expression of CTGF
in control and Pravastatin treated cells: Pravastatin treatment for 24 hours inhibits CTGF protein expression showing also a dose-response
relationship. GAPDH is used as a housekeeping gene. C: control, P: Pravastatin treatment. 0.1, 0.5 refer to treatment dose in mM.
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symptoms associated with radiation-induced plexopathies
[45]. The efficacy of this triple combination is currently
validated in a phase III randomized clinical trial that has
started at Saint Louis Hospital for radiation-induced
plexitis (support by the French Ministry of Health, PHRC
2009). Therefore, understanding the molecular mechan-
ism of PTX-Vit.E combination solicit much interest for
better understanding of radiation-induced fibrosis, to
improve treatment robustness and will pave the way
toward new more efficient treatments.
Vitamin E (a-tocopherol) is an antioxidant drug known
to modulate the expression of several genes such as
ICAM-1 integrins and PPAR-gamma [46]. a-tocopherol
was reported to decrease the expression of genes known
to be involved in the fibrotic process such as (MMP-1) in
human skin fibroblast [47], and IL-1b in THP-1 cells [48].
In mice, D-a-tocopherol supplementation decreased col-
lagen mRNA in the liver by 70% [49]. In type 2 diabetic
patients, a-tocopherol supplementation lowered plasma
levels of PAI-1 and P-selectin [50]. In other case, a-toco-
pherol induces the expression of CTGF in human smooth
muscle cells while neither b-tocopherol nor N-acetylcys-
teine do [51]. It was suggested that this modulation of
CTGF was unique as it was not triggered by structurally
related antioxidant molecules, suggesting occurrence of a
non-antioxidant mechanism in the transcriptional regula-
tion of several genes.
Pentoxifylline, PTX is a methylxanthine derivative used
to treat vascular disease such as intermittent claudication.
In vivo, it has been reported to have anti-TNF-a effect,
increase erythrocyte flexibility, vasodilate, and inhibit
inflammatory reactions. In vitro studies have indicated
that PTX has also antioxidant properties [52], inhibits
human dermal fibroblast proliferation and extracellular
matrix production [53-55] and increases collagenase
activity [53]. However, the doses of pentoxifylline
required to produce these effects in vitro are high, and
reached 1000 μg/ml in some cases [54] rendering in vivo
use of PTX unsuitable. In addition, PTX is known as a
non-specific phosphodiesterases inhibitor that subse-
quently increases intracellular levels of cAMP. Like other
cAMP elevating agents PTX could activate protein kinase
A (PKA) which would phosphorylate transcription fac-
tors, such as cAMP response element binding protein
(CREB). Activated CREB recruits the coactivators CBP
and P300 that also act as transcriptional co-activators for
SMADs [56,57]. Therefore, the sequestration of CBP/
P300 by activated CREB could inhibit SMAD-dependent
transcription [58] and constitute one molecular mechan-
ism to explain PTX anti-fibrotic action that remains to
be demonstrated in vivo. For example, in a model RIF-
induced in pigs no clinical or histological changes were
observed in RIF after 6 months of treatment with PTX
alone using maximum tolerated dose [41]. Extrapolation
from in vitro studies would however suggest that higher
concentration of PTX would be required to achieve effec-
tive suppression of collagen synthesis or to increase col-
lagenase activity. Used at this dosage, PTX might be
extremely toxic and suggests that administration of PTX
alone does not constitute an anti-fibrotic treatment.
Studies about the mechanism of action of combined
pentoxifylline-vitamin E in radiation fibrosis are awfully
limited. An in vitro study was conducted in dermal fibro-
blast using the water-soluble analogue of vitamin E, trolox,
to investigate the effects of combined pentoxifylline-trolox
on irradiated cells. This study showed reduction in acute
and late ROS formation in cells after irradiation, decrease
in DNA strand breaks whenever the drugs were added i.e.
before or after irradiation supporting an immediate anti-
oxidant action that interfere with the DNA repair process
[59]. However, the relevance of this study to fibrosis is
unclear since only short term response was investigated,
therefore we aimed at investigating the role of combined
pentoxifylline-vitamin E on two well know fibrogenic
pathway, i.e. TGF-b1 and Rho/Rock using an in vitro
model of radiation-induced fibrosis consisting of primary
smooth muscle cells derived from human radiation
enteropathy samples (RE-SMC). The hydrophilic analo-
gous of a-tocopherol, trolox, was used. Incubation of the
cells with combined pentoxifylline-trolox didn’t regulate
RhoB mRNA expression (Figure 2A) nor influence Actin
cytoskeleton in RE-SMC (data not shown) but interest-
ingly negatively modulated TGF-b1 mRNA expression at
early time point (one hour post-treatment) and subse-
quently decrease the expression of TGF-b1 targets such as
PAI-1 both at mRNA and protein levels (twenty four
hours post-treatment) (Figure 2A and 2B). This suggested
that the anti-fibrotic effects of combined pentoxifylline-
trolox could be mediated by inhibition of the TGF-b1
pathway. Interestingly, pentoxifylline and trolox appear to
enhance the activity of each other; and the effect of the
combination was more potent than any of the individual
treatments, which is the definition of drugs synergy. Com-
bined pentoxifylline-trolox with a dose of 10 μg/ml
decreases protein expression of PAI-1 more effectively
than trolox alone (10 μg/ml) or pentoxifylline alone
(10 μg/ml) (Figure 2B). Thus, the synergy between the ele-
ments of this combination at low concentration could
constitute the basis of its efficacy conferring a more appro-
priate therapeutic window. This study offers for the first
time, to our knowledge, a molecular base for rationaliza-
tion of the clinical use of combined Pentoxifylline-vitamin
E in radiation fibrosis. Nevertheless, inhibition of TGF-b1
pathway is unlikely to be the sole anti-fibrotic mechanism
of action of combined pentoxifylline-trolox and other
novel candidates are actually under investigations.
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Conclusion
From molecular profiling to clinical trials in a bottom-
up manner or from the clinical trials to the molecular
understanding in a top-down approach, these studies
have optimized our understanding of radiation-induced
fibrogenesis. Combining these information could ulti-
mately lead to improve management of fibrosis.
In a model of intestinal fibrosis, Statins act principally
via inhibition of Rho/Rock pathway decreasing subse-
quently the expression of CTGF. In contrast, combined
pentoxifylline-trolox inhibits TGF-b1 pathway while it
appears to have no influence on Rho/Rock pathway.
Therefore combining these two medications to generate a
more efficient triple therapy seemed a logical follow up.
While emerging new combinations might be promising,
heavy investigations are needed to prove their safety and
efficacy over already solid candidates as Statins or com-
bined pentoxifylline-vitamin E.
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